Researchers: Zeming Wu, Jie Ren, Guang-Hui Liu
N6 -methyladenosine (m6 A) is a dynamic and reversible RNA modification that has emerged as a crucial player in the life cycle of RNA, thus playing a pivotal role in various biological processes. In recent years, the potential involvement of RNA m6 A modification in aging and age-related diseases has gained increasing attention, making it a promising target for understanding the molecular mechanisms underlying aging and developing new therapeutic strategies. This Perspective article will summarize the current advances in aging-related m6 A regulation, highlighting the most significant findings and their implications for our understanding of cellular senescence and aging, and the potential for targeting RNA m6 A regulation as a therapeutic strategy. We will also discuss the limitations and challenges in this field and provide insights into future research directions. By providing a comprehensive overview of the current state of the field, this Perspective article aims to facilitate further advances in our understanding of the molecular mechanisms underlying aging and to identify new therapeutic targets for aging-related diseases.
References
- Biomarkers of aging.
- Targeting senescent cells for a healthier longevity: the roadmap for an era of global aging.
- MAVS Antagonizes Human Stem Cell Senescence as a Mitochondrial Stabilizer.
- Epigenetic regulation of aging: implications for interventions of aging and diseases.
Topic: Precision medicine in aging